DiaMonTech GmbH

  • Land: Deutschland

Nachricht vom 09.09.2019 | 09:00

DiaMonTech successfully concludes financing round of more than 7 million Euro

DGAP-News: DiaMonTech GmbH / Key word(s): Financing

09.09.2019 / 09:00
The issuer is solely responsible for the content of this announcement.


DiaMonTech successfully concludes financing round of more than 7 million Euro

Berlin, 9 September 2019


DiaMonTech GmbH, a young and innovative medical technology company, has successfully completed its Series A financing round. The company will receive a total of more than 7 million euros. The lead investor for this growth financing is Bioventure, an investor specialized in biotech and life science. In addition, DiaMonTech has gained two family offices as new investors. Existing shareholders - such as IBB Beteiligungsgesellschaft via its fund "VC Fonds Technologie Berlin" - also participated in the financing round.

DiaMonTech's goal is to provide diabetes patients worldwide with a groundbreaking technology for measuring blood glucose levels. The patented technology enables non-invasive blood glucose measurement using a laser-based diagnostic procedure. The blood glucose level can be measured precisely and painlessly without the need for a drop of blood. DiaMonTech's first product - the "DMT Base" - recently received CE certification as a medical device. The device is currently optimized for the use in professional environments (e.g. diabetes centers). The smaller "DMT Pocket" is currently in development. This product is supposed to have the size of a smartphone and could therefore become a constant accompaniment for diabetes patients.

DiaMonTech intends to use the proceeds from this financing round to further develop and optimize its non-invasive blood glucose monitoring technologies.

Thorsten Lubinski, co-founder and CEO of DiaMonTech GmbH: "With Bioventure we have gained a prominent life sciences investor with an excellent network. Their commitment confirms that we are on the right track. Our goal is to allow diabetes patients to measure their blood glucose continuously and painlessly with a wristband. The new capital will enable us to drive our groundbreaking diagnostic technology even faster."

Dr. Erik Hoppe, Managing Partner of Bioventure: "DiaMonTech is developing an innovative and very convincing solution for diabetes patients worldwide with non-invasive blood glucose monitoring. It offers the opportunity to significantly improve the quality of life of those affected. We anticipate an outstanding market potential. In Germany alone, about 7.2 million people are currently affected by diabetes".

To date, most diabetes patients still use the same method as they did thirty years ago - with a needle and test strips. Similar to a finger print sensor on a modern mobile phone, one can put ones finger on the sensor of the DiaMonTech device and after a few brief seconds it displays ones blood glucose level.

About DiaMonTech
DiaMonTech GmbH is a medical technology company that specializes in the development, design and sale of products for medical diagnostics. The patented photothermal diagnostic technology based on infrared lasers enables the precise measurement of relevant blood parameters. The first application is the non-invasive blood glucose measurement, which enables an accurate and fast measurement without pain.

More information about DiaMonTech can be found at www.diamontech.de.

Press contact
Alexander Neblung
Kirchhoff Consult AG
Phone +49 40 60 91 86 70
E-mail diamontech@kirchhoff.de



09.09.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this

GBC-Fokusbox

Expedeon AG mit attraktiver Produktpipeline

Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.

News im Fokus

Wirecard AG startet Aktienrückkaufprogramm in Höhe von bis zu 200 Mio. EUR

18. Oktober 2019, 16:04

Aktuelle Research-Studie

ad pepper media International N.V.

Original-Research: ad pepper media International N.V. (von First Berlin Equity Research GmbH): Hinzufügen

18. Oktober 2019